U.S. markets close in 30 minutes

Puma Biotechnology, Inc. (PBYI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.21-0.52 (-4.43%)
As of 3:30PM EST. Market open.

Puma Biotechnology, Inc.

10880 Wilshire Boulevard
Suite 2150
Los Angeles, CA 90024
United States
424 248 6500

Full Time Employees269

Key Executives

NameTitlePayExercisedYear Born
Mr. Alan H. AuerbachFounder, Chairman, Pres, CEO & Sec.1.3MN/A1970
Mr. Maximo F. NouguesCFO & Principal Accounting Officer665.8kN/A1969
Dr. Richard P. BryceChief Medical & Scientific Officer720.3kN/A1957
Mr. Douglas HuntSr. VP of Regulatory Affairs, Medical Writing & Project Management523.83kN/A1965
Mr. Mariann OhanesianSr. Director of Investor RelationsN/AN/AN/A
Charon Spencer Sr.VP of HRN/AN/AN/A
Mr. Jeffrey Jerome LudwigChief Commercial OfficerN/AN/A1966
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. The company was founded in 2010 and is headquartered in Los Angeles, California.

Corporate Governance

Puma Biotechnology, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.